介入治疗肝癌患者甲胎蛋白异质体的变化

The Changes of the AFP-L3 in treatment of HCC patients with interventional therapy

目的探讨肝动脉化疗栓塞(TACE)对肝细胞癌(HCC)患者甲胎蛋白异质体(AFPL3)的影响。方法用酶联免疫法测定HCC患者术前、术后1周血清AFP、AFP-L3%(AFP-L3/AFP百分比)的数值。结果术后1周AFP-L3%的值与术前比较,差异有统计学意义(P<0.001)。结论 HCC患者接受TACE治疗后,AFP-L3%的数值明显降低,AFP-L3%可能成为HCC患者治疗的评估指标。

Objective To investigate the influence of the AFP-L3 in treatment of hepatocellular carcinoma（HCC） patients with transcatheter arterial chemoembolization（TACE）.Methods Determination of the serum AFP,AFP-L3% of HCC patients before or after one weeks,by enzyme linked immunosorbent assay.Results One weeks after the operation,the value of AFP-L3% compared with those before operation,the difference was significantly（P 0.001）.Conclusions In treatment of hepatocellular carcinoma（HCC） patients with transcatheter arterial chemoembolization（TACE）,the values of AFP-L3% of was decrease significantly;And the AFP-L3% of the HCC may be used as evaluation index for the treatment of patients.